Lyra Therapeutics (NASDAQ:LYRA) Trading Down 15% – Should You Sell?

Lyra Therapeutics, Inc. (NASDAQ:LYRA)’s share price traded down 15% during trading on Wednesday . The stock traded as low as $0.51 and last traded at $0.51. 15,603 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 56,719 shares. The stock had previously closed at $0.60.

Lyra Therapeutics Stock Performance

The company has a market capitalization of $905,250.00, a price-to-earnings ratio of -0.02 and a beta of 0.68. The business’s 50 day moving average is $0.68 and its 200 day moving average is $1.27.

Institutional Investors Weigh In On Lyra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in shares of Lyra Therapeutics by 33.7% during the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after buying an additional 7,190 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Lyra Therapeutics during the 3rd quarter worth about $128,000. DRW Securities LLC acquired a new stake in Lyra Therapeutics during the 4th quarter worth about $52,000. Sabby Management LLC lifted its position in Lyra Therapeutics by 37.2% during the 4th quarter. Sabby Management LLC now owns 175,158 shares of the company’s stock worth $539,000 after acquiring an additional 47,534 shares during the period. Finally, Artia Global Partners LP purchased a new stake in Lyra Therapeutics during the 4th quarter valued at about $27,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).